An overview of functional, structural and neurochemical imaging studies in individuals with a clinical high risk for psychosis

Neuropsychiatry

Volumn 1, Issue 5, 2011, Pages 477-493

  Egerton, Alice ^a,b   Borgwardt, Stefan J ^c   Tognin, Stefania ^a   Howes, Oliver D ^a,b   McGuire, Philip ^a   Allen, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DOPA; DOPAMINE; FLUORINE 18; GLUTAMIC ACID; N ACETYLASPARTIC ACID; NEUROTRANSMITTER; SEROTONIN; SEROTONIN 2A RECEPTOR;

BRAIN BLOOD VOLUME; BRAIN FUNCTION; DISEASE COURSE; DISEASE SEVERITY; EARLY INTERVENTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HIGH RISK POPULATION; HUMAN; MIDDLE TEMPORAL GYRUS; NEUROANATOMY; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUPERIOR TEMPORAL GYRUS; TASK PERFORMANCE; TREATMENT OUTCOME;

EID: 84876510206     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.11.51     Document Type: Review

References (125)

1. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosis-prone subjects 10 years later. J. Abnorm. Psychol. 103, 171-183 (1994). (Pubitemid 24152791)
2. Yung AR, Phillips LJ, McGorry PD et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatr. Suppl. 172, 14-20 (1998). (Pubitemid 28258893)
3. Hafner H. Prevention and early intervention in schizophrenia: facts and visions. Seishin Shinkeigaku Zasshi 104, 1033-1054 (2002).
4. Riecher-Rossler A, Gschwandtner U, Borgwardt S, Aston J, Pfluger M, Rossler W. Early detection and treatment of schizophrenia: how early? Acta Psychiatr. Scand. Suppl. (429), 73-80 (2006). (Pubitemid 43340893)
5. Ragland JD, Yoon J, Minzenberg MJ, Carter CS. Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism. Int. Rev. Psychiatr. 19, 417-427 (2007).
6. Ranganath C, Minzenberg MJ, Ragland JD. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol. Psychiatr. 64, 18-25 (2008).
7. Achim AM, Lepage M. Episodic memory-related activation in schizophrenia: meta-analysis. Br. J. Psychiatr. 187, 500-509 (2005). (Pubitemid 41752738)
8. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatr. 66, 811-822 (2009).
9. Costafreda SG, Fu CH, Lee L, Everitt B, Brammer MJ, David AS. A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. Hum. Brain Mapp. 27, 799-810 (2006). (Pubitemid 44522568)
10. Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch. Gen. Psychiatr. 62, 254-262 (2005). (Pubitemid 40990970)
11. Broome MR, Matthiasson P, Fusar-Poli P et al. Neural correlates of executive function and working memory in the 'at-risk mental state'. Br. J. Psychiatr. 194, 25-33 (2009).
12. Fusar-Poli P, Broome MR, Matthiasson P et al. Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. Schizophr. Bull. 37, 189-198 (2011).
13. Sabb FW, van Erp TG, Hardt ME et al. Language network dysfunction as a predictor of outcome in youth at clinical high risk for psychosis. Schizophr. Res. 116, 173-183 (2010).
14. Pukrop R, Ruhrmann S, Schultze-Lutter F, Bechdolf A, Brockhaus-Dumke A, Klosterkotter J. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr. Res. 92, 116-125 (2007). (Pubitemid 46561233)
15. Brewer WJ, Francey SM, Wood SJ et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatr. 162, 71-78 (2005). (Pubitemid 40095675)
16. Lencz T, Smith CW, McLaughlin D et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatr. 59, 863-871 (2006).
17. Allen P, Seal ML, Valli I et al. Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. Schizophr. Bull. 37(4), 746-756 (2011).
18. Broome MR, Fusar-Poli P, Matthiasson P et al. Neural correlates of visuospatial working memory in the 'at-risk mental state'. Psychol. Med. 40, 1987-1999 (2010).
19. Hasselmo ME, Stern CE. Mechanisms underlying working memory for novel information. Trends Cogn. Sci. 10, 487-493 (2006). (Pubitemid 44602572)
20. Ranganath C, D'Esposito M. Medial temporal lobe activity associated with active maintenance of novel information. Neuron 31, 865-873 (2001). (Pubitemid 32907380)
21. Fusar-Poli P, Broome MR, Matthiasson P et al. Spatial working memory in individuals at high risk for psychosis: longitudinal fMRI study. Schizophr. Res. 123, 45-52 (2010).
22. Broome MR, Matthiasson P, Fusar-Poli P et al. Neural correlates of movement generation in the 'at-risk mental state'. Acta Psychiatr. Scand. 122, 295-301 (2010).
23. Walterfang M, Wood SJ, Velakoulis D, Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci. Biobehav. Rev. 30, 918-948 (2006). (Pubitemid 44292852)
24. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatr. 59, 929-939 (2006). (Pubitemid 44288017)
25. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 35, 509-527 (2009).
26. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatr. 59, 929-939 (2006). (Pubitemid 44288017)
27. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 35, 509-527 (2009).
28. Friston KJ, Harrison L, Penny W. Dynamic causal modelling. Neuroimage 19, 1273-1302 (2003). (Pubitemid 37025831)
29. Pettersson-Yeo W, Allen P, Benetti S, McGuire P, Mechelli A. Dysconnectivity in schizophrenia: where are we now? Neurosci. Biobehav. Rev. 35(5), 1110-1124 (2011).
30. Friston KJ. The disconnection hypothesis. Schizophr. Res. 30, 115-125 (1998). (Pubitemid 28156976)
31. Frith CD, Friston KJ, Herold S et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br. J. Psychiatr. 167, 343-349 (1995). (Pubitemid 26197748)
32. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin. Neurosci. 3, 89-97 (1995).
33. Benetti S, Mechelli A, Picchioni M, Broome M, Williams S, McGuire P. Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain 132(Pt 9), 2426-2436 (2009).
34. Allen P, Stephan KE, Mechelli A et al. Cingulate activity and fronto-temporal connectivity in people with prodromal signs of psychosis. Neuroimage 49, 947-955 (2010).
35. Crossley NA, Mechelli A, Fusar-Poli P et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum. Brain Mapp. 30(12), 4129-4137 (2009).
36. Lord LD, Allen P, Expert P et al. Characterization of the anterior cingulate's role in the at-risk mental state using graph theory. Neuroimage 56(3), 1531-1539 (2011).
37. Schobel SA, Lewandowski NM, Corcoran CM et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch. Gen. Psychiatr. 66, 938-946 (2009).
38. Broome MR, Matthiasson P, Fusar-Poli P et al. Neural correlates of executive function and working memory in the 'at-risk mental state'. Br. J. Psychiatr. 194, 25-33 (2009).
39. Callicott JH, Bertolino A, Mattay VS et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex. 10, 1078-1092 (2000).
40. Schlosser RG, Koch K, Wagner G et al. Inefficient executive cognitive control in schizophrenia is preceded by altered functional activation during information encoding: an fMRI study. Neuropsychologia 46, 336-347 (2008).
41. Tan HY, Sust S, Buckholtz JW et al. Dysfunctional prefrontal regional specialization and compensation in schizophrenia. Am. J. Psychiatr. 163, 1969-1977 (2006). (Pubitemid 44807789)
42. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatr. 157, 16-25 (2000). (Pubitemid 30027416)
43. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52 (2001). (Pubitemid 32451739)
44. Ho BC, Alicata D, Ward J et al. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am. J. Psychiatr. 160, 142-148 (2003). (Pubitemid 36042438)
45. Lieberman J, Chakos M, Wu H. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatr. 49, 487-499 (2001). (Pubitemid 32226407)
46. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N. Engl. J. Med. 322, 789-794 (1990). (Pubitemid 20094141)
47. Staal WG, Hulshoff Pol HE, Schnack HG, Hoogendoorn ML, Jellema K, Kahn RS. Structural brain abnormalities in patients with schizophrenia and their healthy siblings. Am. J. Psychiatr. 157, 416-421 (2000). (Pubitemid 30145928)
48. Baare WF, van Oel CJ, Hulshoff Pol HE et al. Volumes of brain structures in twins discordant for schizophrenia. Arch. Gen. Psychiatr. 58, 33-40 (2001). (Pubitemid 32057763)
49. Lawrie SM, Whalley H, Kestelman JN et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 353, 30-33 (1999). (Pubitemid 29037700)
50. Keshavan MS, Montrose DM, Pierri JN et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies. Prog. Neuropsychopharmacol. Biol. Psychiatr. 21, 1285-1295 (1997). (Pubitemid 28046701)
51. Sharma T, Lancaster E, Lee D et al. Brain changes in schizophrenia. Volumetric MRI study of families multiply affected with schizophrenia-the Maudsley Family Study 5. Br. J. Psychiatr. 173, 132-138 (1998). (Pubitemid 28368362)
52. Hulshoff Pol HE, Brans RG, van Haren NE et al. Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophrenia. Biol. Psychiatr. 55, 126-130 (2004). (Pubitemid 38367715)
53. van Haren NE, Picchioni MM, McDonald C et al. A controlled study of brain structure in monozygotic twins concordant and discordant for schizophrenia. Biol. Psychiatr. 56, 454-461 (2004). (Pubitemid 39195326)
54. Borgwardt SJ, Picchioni MM, Ettinger U, Toulopoulou T, Murray R, McGuire PK. Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia. Biol. Psychiatr. 67, 956-964 (2010).
55. Cannon TD, Thompson PM, van Erp TG et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc. Natl Acad. Sci. USA 99, 3228-3233 (2002). (Pubitemid 34240614)
56. Narr KL, van Erp TG, Cannon TD et al. A twin study of genetic contributions to hippocampal morphology in schizophrenia. Neurobiol. Dis. 11, 83-95 (2002). (Pubitemid 35435676)
57. Pantelis C, Yucel M, Wood SJ et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 31, 672-696 (2005). (Pubitemid 41253318)
58. Borgwardt SJ, Dickey C, Hulshoff Pol H, Whitford TJ, DeLisi LE. Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona. The Rapporteurs' Report. Schizophr. Res. 112, 32-45 (2009).
59. Job DE, Whalley HC, McConnell S, Glabus M, Johnstone EC, Lawrie SM. Voxel-based morphometry of grey matter densities in subjects at high risk of schizophrenia. Schizophr. Res. 64, 1-13 (2003). (Pubitemid 37153344)
60. Phillips LJ, Velakoulis D, Pantelis C et al. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr. Res. 58, 145-158 (2002). (Pubitemid 35284506)
61. Takahashi T, Wood SJ, Yung AR et al. Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. Schizophr. Res. 111, 94-102 (2009).
62. Takahashi T, Wood SJ, Yung AR et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch. Gen. Psychiatr. 66, 366-376 (2009).
63. Garner B, Pariante CM, Wood SJ et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol. Psychiatr. 58, 417-423 (2005). (Pubitemid 41219710)
64. Wood SJ, Yucel M, Velakoulis D et al. Hippocampal and anterior cingulate morphology in subjects at ultra-high-risk for psychosis: the role of family history of psychotic illness. Schizophr. Res. 75, 295-301 (2005). (Pubitemid 40693061)
65. Velakoulis D, Wood SJ, Wong MT et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatr. 63, 139-149 (2006). (Pubitemid 43213875)
66. Meisenzahl EM, Koutsouleris N, Gaser C et al. Structural brain alterations in subjects at high-risk of psychosis: a voxel-based morphometric study. Schizophr. Res. 102, 150-162 (2008).
67. Pantelis C, Velakoulis D, McGorry PD et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361, 281-288 (2003). (Pubitemid 36126187)
68. Borgwardt SJ, Riecher-Rossler A, Dazzan P et al. Regional gray matter volume abnormalities in the at risk mental state. Biol. Psychiatr. 61, 1148-1156 (2007). (Pubitemid 46669460)
69. Fornito A, Yung AR, Wood SJ et al. Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: an MRI study of ultra-high-risk individuals. Biol. Psychiatr. 64(9), 758-765 (2008).
70. Walterfang M, McGuire PK, Yung AR et al. White matter volume changes in people who develop psychosis. Br. J. Psychiatr. 193, 210-215 (2008).
71. Wood SJ, Pantelis C, Velakoulis D, Yucel M, Fornito A, McGorry PD. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr. Bull. 34, 322-329 (2008). (Pubitemid 351323332)
72. Job DE, Whalley HC, Johnstone EC, Lawrie SM. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage 25, 1023-1030 (2005). (Pubitemid 40591646)
73. Farrow TF, Whitford TJ, Williams LM, Gomes L, Harris AW. Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder. Biol. Psychiatr. 58, 713-723 (2005). (Pubitemid 41547239)
74. Borgwardt SJ, McGuire PK, Aston J et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr. Res. 106(2-3), 108-114 (2008).
75. Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr. Res. 108(1-3), 85-92 (2008).
76. Cahn W, Hulshoff Pol HE, Lems EB et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatr. 59, 1002-1010 (2002).
77. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatr. 60, 585-594 (2003). (Pubitemid 36682316)
78. Kasai K, Shenton ME, Salisbury DF et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am. J. Psychiatr. 160, 156-164 (2003). (Pubitemid 36042440)
79. Kubicki M, Shenton ME, Salisbury DF et al. Voxel-based morphometric analysis of gray matter in first episode schizophrenia. Neuroimage 17, 1711-1719 (2002). (Pubitemid 36062762)
80. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatr. 58, 148-157 (2001). (Pubitemid 32142752)
81. Sporn AL, Greenstein DK, Gogtay N et al. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am. J. Psychiatr. 160, 2181-2189 (2003). (Pubitemid 39619611)
82. Fusar-Poli P, Borgwardt S, Crescini A et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci. Biobehav. Rev. 35, 1175-1185 (2011).
83. Koutsouleris N, Meisenzahl EM, Davatzikos C et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch. Gen. Psychiatr. 66, 700-712 (2009).
84. Koutsouleris N, Gaser C, Bottlender R et al. Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. Schizophr. Res. 123, 175-187 (2010).
85. Fusar-Poli P, Broome MR, Matthiasson P, Williams SC, Brammer M, McGuire PK. Effects of acute antipsychotic treatment on brain activation in first episode psychosis: an fMRI study. Eur. Neuropsychopharmacol. 17, 492-500 (2007). (Pubitemid 46509566)
86. Smieskova R, Fusar-Poli P, Allen P et al. The effects of antipsychotics on the brain: what have we learnt from structural neuroimaging of schizophrenia?-a systematic review. Curr. Pharmaceut. Desig. 15, 2535-2549 (2009).
87. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatr. 68, 128-137 (2011).
88. Jung WH, Kim JS, Jang JH et al. Cortical thickness reduction in individuals at ultra-high-risk for psychosis. Schizophr. Bull. 37, 839-849 (2011).
89. Cachia A, Paillere-Martinot ML, Galinowski A et al. Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations. Neuroimage 39, 927-935 (2008).
90. Price G, Cercignani M, Chu EM et al. Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss. Neuroimage 49, 185-192 (2010).
91. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatr. 158, 1367-1377 (2001). (Pubitemid 32847232)
92. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatr. 52, 998-1007 (1995).
93. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann. Rev. Pharmacol. Toxicol. 41, 237-260 (2001). (Pubitemid 32385889)
94. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81, 89-131 (2007). (Pubitemid 46282272)
95. Jessen F, Scherk H, Traber F et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res. 87, 81-88 (2006). (Pubitemid 44428131)
96. Wood SJ, Berger G, Velakoulis D et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr. Bull. 29, 831-843 (2003). (Pubitemid 38181959)
97. Wood SJ, Berger GE, Wellard RM et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol. Dis. 33, 354-357 (2009).
98. Stone JM, Day F, Tsagaraki H et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatr. 66, 533-539 (2009).
99. Byun MS, Choi JS, Yoo SY et al. Depressive symptoms and brain metabolite alterations in subjects at ultra-high risk for psychosis: a preliminary study. Psychiatr. Invest. 6, 264-271 (2009).
100. Uhl I, Mavrogiorgou P, Norra C et al. 1H-MR spectroscopy in ultra-high risk and first episode stages of schizophrenia. J. Psychiatr. Res. 45(9), 1135-1139 (2011).
101. Aydin K, Ucok A, Guler J. Altered metabolic integrity of corpus callosum among individuals at ultra high risk of schizophrenia and first-episode patients. Biol. Psychiatr. 64, 750-757 (2008).
102. Theberge J, Bartha R, Drost DJ et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatr. 159, 1944-1946 (2002). (Pubitemid 35283267)
103. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30, 1949-1962 (2005). (Pubitemid 43093497)
104. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol. Psychiatr. 69, 495-503 (2011).
105. Aydin K, Ucok A, Cakir S. Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection. AJNR Am. J. Neuroradiol. 28, 1968-1974 (2007). (Pubitemid 350174744)
106. Wood SJ, Kennedy D, Phillips LJ et al. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 52, 62-68 (2010).
107. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatr. Suppl. 51, S13-S18 (2007). (Pubitemid 350273183)
108. Cumming P, Leger GC, Kuwabara H, Gjedde A. Pharmacokinetics of plasma 6-[18F] fluoro-l-3,4-dihydroxyphenylalanine ([18F] Fdopa) in humans. J. Cereb. Blood Flow Metab. 13, 668-675 (1993). (Pubitemid 23187510)
109. Howes OD, Montgomery AJ, Asselin MC et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatr. 66, 13-20 (2009).
110. Howes O, Bose S, Turkheimer F et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatr. 16(9), 885-886 (2011).
111. Hurlemann R, Matusch A, Kuhn KU et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl.) 195(4), 579-590 (2008). (Pubitemid 350160486)
112. Theberge J, Williamson KE, Aoyama N et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatr. 191, 325-334 (2007). (Pubitemid 47555981)
113. Stone JM, Bramon E, Pauls A, Sumich A, McGuire PK. Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia- relationship to auditory event-related potentials. Psychiatr. Res. 183, 174-176 (2010).
114. Klostermann F, Wahl M, Marzinzik F, Schneider GH, Kupsch A, Curio G. Mental chronometry of target detection: human thalamus leads cortex. Brain 129, 923-931 (2006).
115. Day M, Langston R, Morris RG. Glutamate-receptor-mediated encoding and retrieval of paired-associate learning. Nature 424, 205-209 (2003). (Pubitemid 36858689)
116. Valli I, Stone J, Mechelli A et al. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol. Psychiatr. 69, 97-99 (2011).
117. Lisman JE, Coyle JT, Green RW et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31, 234-242 (2008).
118. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 31, 1356-1361 (2006).
119. Stone JM, Howes OD, Egerton A et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol. Psychiatr. 68, 599-602 (2010).
120. Fusar-Poli P, Howes OD, Allen P et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatr. 67, 683-691 (2010).
121. Fusar-Poli P, Howes OD, Allen P et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatr. 16, 67-75 (2011).
122. Allen P, Chaddock CA, Howes O et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr. Bull. doi: 10.1093/schbul/sbr017 (2011) (Epub ahead of print).
123. Yung AR, Yuen HP, Berger G et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr. Bull. 33, 673-681 (2007). (Pubitemid 47343718)
124. Broome MR, Woolley JB, Johns LC et al. Outreach and Support in South London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur. Psychiatr. 20, 372-378 (2005). (Pubitemid 41318002)
125. Valmaggia LR, McCrone P, Knapp M et al. Economic impact of early intervention in people at high risk of psychosis. Psychol. Med. 39(10), 1617-1626 (2009).